Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Technology / Oncoinvent publishes Radspherin...
Tech clinical data publication

Oncoinvent publishes Radspherin dosimetry results

Analysis based on 6 articles · First reported Aug 11, 2026 · Last updated Aug 11, 2026

Sentiment
30
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The publication of favorable dosimetry data in a prestigious journal enhances the credibility of Radspherin's safety profile, potentially increasing investor confidence in Oncoinvent's pipeline. This could positively impact Oncoinvent's valuation and its attractiveness to potential pharmaceutical partners, though the company is privately held.

Biotechnology Pharmaceuticals Healthcare
Event Summary

Oncoinvent, a biotech company developing Radspherin, an alpha radiopharmaceutical for treating peritoneal metastases, announced the publication of clinical dosimetry data in the The Journal of Nuclear Medicine. The publication, titled 'Normal Tissue Dosimetry of Intraperitoneal Radium-224-Microparticle Therapy: Data from First-in-Human Studies in Patients with Peritoneal Metastases', reports results from nine patients in the dosimetry cohorts of Phase 1 studies in ovarian and colorectal cancer. The data show that absorbed radiation doses to normal organs, including kidneys and red bone marrow, were well below levels associated with toxicity risks. This supports the favorable safety profile observed in clinical trials and the continued development of Radspherin. The study was conducted at The Norwegian Radium Hospital, part of Oslo University Hospital, with contributions from Caroline Stage Olsen and Kari Myren. Oncoinvent expects interim data from an ongoing Phase 2 ovarian cancer trial in 2026.

Key Actions
70 Oncoinvent reached milestone
Entities Involved
priv
Oncoinvent
Oncoinvent is the developer of Radspherin and the primary subject of the announcement. The publication of favorable dosimetry data supports its clinical program and could enhance its commercial prospects.
Importance 100.0 Sentiment 70.0
per
Caroline Stage Olsen
Caroline Stage Olsen is the senior author of the publication and Head of Nuclear Medicine Physics at Oslo University Hospital. Her involvement lends scientific authority to the results.
Importance 30.0 Sentiment 20.0
per
Kari Myren
Kari Myren is the Chief Medical Officer at Oncoinvent and is quoted in the announcement. Her statements reinforce the safety and development potential of Radspherin.
Importance 30.0 Sentiment 20.0
per
Øystein Soug
Øystein Soug is the CEO of Oncoinvent and is listed as a contact. His role is administrative in this context.
Importance 10.0 Sentiment 10.0
ngo
European Association of Nuclear Medicine
Caroline Stage Olsen chairs its Dosimetry Committee, but the association itself is not directly involved in the event.
Importance 10.0 Sentiment 10.0
stock
Bayer
Bayer is mentioned as the acquirer of Algeta and Xofigo, providing background on Oncoinvent's founders. No direct impact on Bayer.
Importance 10.0 Sentiment 10.0
priv
Algeta
Algeta is mentioned as the originator company of Xofigo, which was acquired by Bayer. It provides context for Oncoinvent's founding team.
Importance 10.0 Sentiment 10.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.